BIEL'S CEO was asked about the crap on IHUB. pk
Post# of 8387
(Total Views: 429)
Posted On: 01/17/2023 9:17:03 AM
BIEL'S CEO was asked about the crap on IHUB.
pknopick@eandecommunications.com
BioElectronic's CEO was asked about the muck and mud at message board IHUB.
(By the way, we recommend Investor's Hangout and StockTwits instead.)
This is her excellent answer:
I am aware of the constant bashing of BioElectronics and its management
that occurs on the IHUB board. We choose to ignore it. Unfortunately,
there will always be negative comments regardless of what we accomplish.
It is easy to criticize, badger and demean in an anonymous forum.
On that note, We have been fortunate have Dr. Brian Ilfeld at UC San
Diego conducting independent research on the device. Following are the
synopses of three case studies:
"These cases demonstrate that following knee and hip arthroplasty, the
use of pulsed shortwave therapy devices is feasible in both the in- and
out-patient settings and may improve analgesia while decreasing—perhaps
sometimes obviating—opioid consumption." Full article
here:https://www.fortunejournals.com/articles/noninvasive-wearable-pulsed-shortwave-radiofrequency-therapy-for-analgesia-following-knee-and-hip-arthroplasty-a-case-series.pdf
"These cases suggest that pulsed electromagnetic field therapy may be an
effective treatment for intractable postamputation pain. Considering the
low patient burden of noninvasive, wearable devices, combined with few
contraindications and no significant side effects or adverse events,
further study with a randomized, controlled trial is warranted." (that
further study is underway at UC San Diego) Full article
here:https://amjcaserep.com/abstract/full/idArt/937549
RecoveryRx was recently used in a series of cases at UC San Diego. This
is from this published case report: "Following moderately painful
ambulatory umbilical (n=3) and inguinal (n=2) hernia repair as well as
bilateral breast surgery (n=2),patients had taped over their incision(s)
1 or 2 nonivasive, wearable, disposable, pulsed shortwave therapy
devices (RecoveryRx)which functioned continuously for 30 days. Average
resting pain scores measured on the 0-10 numeric rating scale were a
median of 0 during the entire treatment period. Six patients avoided
opioid use entirely, while the remaining individual required only 5 mg
of oxycodone during the first postoperative day."
The full case study is available here:
https://pubmed.ncbi.nlm.nih.gov/36463434
Wearable, noninvasive, pulsed shortwave (radiofrequency) therapy for analgesia and opioid sparing following outpatient surgery: A proof-of-concept case series - PubMed
These cases demonstrate that the ambulatory use of pulsed shortwave devices is feasible and may be an effective analgesic, possibly obviating opioid requirements following outpatient herniorrhaphy and breast surgery. Considering the lack of any side effects, adverse events, and misuse/dependence/div …
pubmed.ncbi.nlm.nih.gov
pknopick@eandecommunications.com
BioElectronic's CEO was asked about the muck and mud at message board IHUB.
(By the way, we recommend Investor's Hangout and StockTwits instead.)
This is her excellent answer:
I am aware of the constant bashing of BioElectronics and its management
that occurs on the IHUB board. We choose to ignore it. Unfortunately,
there will always be negative comments regardless of what we accomplish.
It is easy to criticize, badger and demean in an anonymous forum.
On that note, We have been fortunate have Dr. Brian Ilfeld at UC San
Diego conducting independent research on the device. Following are the
synopses of three case studies:
"These cases demonstrate that following knee and hip arthroplasty, the
use of pulsed shortwave therapy devices is feasible in both the in- and
out-patient settings and may improve analgesia while decreasing—perhaps
sometimes obviating—opioid consumption." Full article
here:https://www.fortunejournals.com/articles/noninvasive-wearable-pulsed-shortwave-radiofrequency-therapy-for-analgesia-following-knee-and-hip-arthroplasty-a-case-series.pdf
"These cases suggest that pulsed electromagnetic field therapy may be an
effective treatment for intractable postamputation pain. Considering the
low patient burden of noninvasive, wearable devices, combined with few
contraindications and no significant side effects or adverse events,
further study with a randomized, controlled trial is warranted." (that
further study is underway at UC San Diego) Full article
here:https://amjcaserep.com/abstract/full/idArt/937549
RecoveryRx was recently used in a series of cases at UC San Diego. This
is from this published case report: "Following moderately painful
ambulatory umbilical (n=3) and inguinal (n=2) hernia repair as well as
bilateral breast surgery (n=2),patients had taped over their incision(s)
1 or 2 nonivasive, wearable, disposable, pulsed shortwave therapy
devices (RecoveryRx)which functioned continuously for 30 days. Average
resting pain scores measured on the 0-10 numeric rating scale were a
median of 0 during the entire treatment period. Six patients avoided
opioid use entirely, while the remaining individual required only 5 mg
of oxycodone during the first postoperative day."
The full case study is available here:
https://pubmed.ncbi.nlm.nih.gov/36463434
Wearable, noninvasive, pulsed shortwave (radiofrequency) therapy for analgesia and opioid sparing following outpatient surgery: A proof-of-concept case series - PubMed
These cases demonstrate that the ambulatory use of pulsed shortwave devices is feasible and may be an effective analgesic, possibly obviating opioid requirements following outpatient herniorrhaphy and breast surgery. Considering the lack of any side effects, adverse events, and misuse/dependence/div …
pubmed.ncbi.nlm.nih.gov
(6)
(0)